PAVmed's Subsidiary Veris Health Raises $2.5 Million in Equity Financing for Innovations

Veris Health Secures $2.5 Million in Funding

PAVmed Inc. has made headlines with its latest financial maneuver, as its subsidiary, Veris Health Inc., raised a substantial $2.5 million through a private equity financing round. This investment is pivotal for the company's ambitious plans to enhance cancer care solutions through innovative technology.

Funding Breakthrough

On June 24, 2025, PAVmed announced that the financing was accomplished by the sale of common stock of Veris Health at a price of $1.40 per share, which places the company's pre-money valuation at approximately $35 million. This successful financial endeavor follows an earlier funding initiative that brought in $2.4 million earlier this year.

Veris Health specializes in advanced personalized cancer care, concentrating on remote patient monitoring. The funds raised will be instrumental in pushing forward the development of its innovative implantable physiological monitor, with expectations of obtaining FDA clearance by 2026. This financing will also support general corporate needs, allowing for continued operational efficacy during product development stages.

The Role of the Implantable Monitor

The implantable physiological monitor is designed to revolutionize patient care by providing continuous health data through wireless communication. This technology will be integrated with Veris's Cancer Care Platform, which is a comprehensive system aimed at offering superior patient management. The monitor will allow both patients and healthcare providers to gain real-time insights into health status, improving the quality of personalized cancer care.

For every share of Veris common stock purchased, investors are granted warrants to acquire additional shares at the same price of $1.40 each. These warrants can be called within 60 days of FDA clearance, underscoring an efficient path to enable further capital through potential exercises, facilitating smoother commercialization once regulatory approvals are met.

Investor Confidence and Future Prospects

Dr. Lishan Aklog, Chairman and CEO of PAVmed, highlighted the significance of this funding round, stating, "This milestone underscores investor confidence in the commercial potential of Veris Health, allowing us to fund development adequately until FDA clearance and subsequent market entry. Our objective remains to provide a robust platform for personalized cancer care."

Veris Health is committed to creating a connected ecosystem for cancer patients, employing their innovative Veris Cancer Care Platform. This platform integrates remote physiological monitoring, symptom reporting, telehealth capabilities, and a seamless connection to electronic health records. It strives to provide timely detection of complications, ultimately minimizing hospital visits and enhancing patient care.

Patients using the platform will receive a special VerisBox containing cutting-edge health monitoring devices that send data directly to their healthcare teams. Additionally, the platform permits users to share health statistics and experiences with their caregivers and family through an intuitive smartphone application.

Veris is also working on driving engagement with cancer treatment centers, ensuring they have access to the tools to enhance patient outcomes further. Interested cancer centers can learn more by visiting Veris Health's website.

About PAVmed Inc.

PAVmed Inc. functions as a diversified medical technology firm, focusing on developing innovative products across medical devices, diagnostics, and digital health sectors. In addition to Veris, PAVmed oversees operations for Lucid Diagnostics, a company specializing in commercial-stage cancer diagnostics, aiming to revolutionize the detection of esophageal precancer.

For more information about PAVmed and their initiatives, check PAVmed's website.

The recent funding achievement positions Veris Health as a notable player in the cancer care industry, advancing technology that promises to reshape patient experiences and improve outcomes through enhanced monitoring solutions. As the company prepares for FDA interactions, stakeholders eagerly anticipate what lies ahead for both Veris Health and the broader PAVmed entity.